Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J Pediatr. 2013 Jan 3;162(6):1222–1227.e2. doi: 10.1016/j.jpeds.2012.11.031

Table 2.

Population characteristics of asthmatic children and young adults who underwent genotyping for CYP3A polymorphisms

Variables Number (%)
Total no. of subjects 734
Subjects receiving daily inhaled glucocorticoids 413 (56.3)
 Fluticasone propionate  268 (36.5)
 Flunisolide  10 (1.4)
 Triamcinolone acetonide  2 (0.3)
 Beclomethasone dipropionate  31 (4.2)
 Budesonide  56 (7.6)
 Ciclesonide  2 (0.3)
 Mometasone  7 (1.0)
 Fluticasone propionate / salmeterol xinafoate  82 (11.2)
 Budesonide / formoterol  11 (1.5)
Age, yrs 8.8 ± 4.3
Sex
 Male 443 (60.5)
 Female 289 (39.5)
Race
 American Indian / Alaskan Native 9 (1.2)
 Asian 6 (0.8)
 Black 24 (3.3)
 Native Hawaiian / Pacific Islander 15 (2.0)
 White 554 (75.5)
 Unknown / Not reported 122 (16.6)
Ethnicity
 Hispanic 102 (14.0)
 Non-Hispanic 211 (28.9)
 Unknown / Not reported 418 (57.2)
Weight, kg 35.1 ± 21.6
Height, cm 124.9 ±.26.6
Asthma control score
 Subjects receiving daily fluticasone 4.8 ± 3.6
 Subjects receiving other inhaled glucocorticoids 4.9 ± 3.6

NOTE: Values are presented as mean + SD where applicable.